Diagnostic accuracy of transthoracic echocardiography for pulmonary hypertension: a systematic review and meta-analysis. Issue 12 (22nd December 2019)

• Record Type: Journal Article
• Authors: Ni, Jin-Rong; Yan, Pei-Jing; Liu, Shi-Dong; Hu, Yuan; Yang, Ke-Hu; Song, Bing; Lei, Jun-Qiang
• Is Part Of: BMJ open. Volume 9:Issue 12(2019)
• Publication Date: 2019-12-22
• Subjects: hypertension -- echocardiography -- diagnostic radiology; Medicine -- Research -- Periodicals; 610.72
• DOI: 10.1136/bmjopen-2019-033084
• Languages: English
• ISSNs: 2044-6055

Abstract

Abstract : Objective: To evaluate the diagnostic accuracy of transthoracic echocardiography (TTE) in patients with pulmonary hypertension (PH). Design: Systematic review and meta-analysis. Data sources and eligibility criteria: Embase, Cochrane Library for clinical trials, PubMed and Web of Science were used to search studies from inception to 19 June, 2019. Studies using both TTE and right heart catheterisation (RHC) to diagnose PH were included. Main results: A total of 27 studies involving 4386 subjects were considered as eligible for analysis. TTE had a pooled sensitivity of 85%, a pooled specificity of 74%, a pooled positive likelihood ratio of 3.2, a pooled negative likelihood ratio of 0.20, a pooled diagnostic OR of 16 and finally an area under the summary receiver operating characteristic curve of 0.88. The subgroup with the shortest time interval between TTE and RHC had the best diagnostic effect, with sensitivity, specificity and area under the curve (AUC) of 88%, 90% and 0.94, respectively. TTE had lower sensitivity (81%), specificity (61%) and AUC (0.73) in the subgroup of patients with definite lung diseases. Subgroup analysis also showed that different thresholds of TTE resulted in a different diagnostic performance in the diagnosis of PH. Conclusion: TTE has a clinical value in diagnosing PH, although it cannot yet replace RHC considered as the gold standard. The accuracy of TTE may be improved by shortening the time interval between TTE and RHC and by developing an appropriate threshold. TTE may not be suitable to assess pulmonary arterial pressure in patients with pulmonary diseases. PROSPERO registration number: PROSPERO CRD42019123289.